Quest Diagnostics said net revenues for the quarter ended September 30, 2025 increased 13.1% compared to the prior year period, with organic growth of 6.8%. DIS revenues increased 13.5%, with recent acquisitions contributing approximately 6.5%.

1. 01

   Quest Diagnostics said net revenues for the quarter ended September 30, 2025 increased 13.1% compared to the prior year period, with organic growth of 6.8%. DIS revenues increased 13.5%, with recent acquisitions contributing approximately 6.5%.

2. 02

   The company said DIS volume for Q3 increased 12.5% compared to the prior year period, with organic volume up 3.9% after excluding the contribution of approximately 8.6% from recent acquisitions. Revenue per requisition was up 0.8%, and on an organic basis increased 3.0%.

3. 03

   Quest Diagnostics said net cash provided by operating activities for the 9 months ended 2025 was $1.4 billion, an increase of $551 million compared to $870 million in the prior year period. Net cash used in financing activities for the same period was $(1.1) billion, which included the repayment of $600 million of senior notes at maturity and the repurchase of $150 million of shares.

4. 04

   The company said results for Q3 2025 were affected by certain items that on a net basis decreased diluted earnings per share by $0.44. The items included pre-tax amortization expense of $39 million recorded in amortization of intangible assets and pre-tax charges of $22 million recorded in other operating expense, net, comprised of a charge to earnings related to legal matters of $15 million.

Key figures

Quarter ended September 30, 2025

Revenue

$2.8B

Operating income

$386M

Net income

$245M

EPS

$2.16

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.